Overview

Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure

Status:
Terminated
Trial end date:
2017-01-11
Target enrollment:
Participant gender:
Summary
This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with CHF after an exercise testing session.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals